DelveInsight's, "Non-Hodgkin Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin Lymphoma Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Non-Hodgkin Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Non-Hodgkin Lymphoma Pipeline Outlook

Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report*July 2024:- Genmab- The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory (R/R) CD30-expressing lymphomas. *July 2024:- Bristol-Myers Squibb- The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader (LDD) of BCL6 (BCL6 LDD), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma. *DelveInsight's Non-Hodgkin Lymphoma Pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Non-Hodgkin Lymphoma treatment. *The leading Non-Hodgkin Lymphoma Companies such as Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others. *Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.

Stay ahead with the most recent pipeline outlook for Non-Hodgkin Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-Hodgkin Lymphoma Treatment

Non-Hodgkin Lymphoma Emerging Drugs Profile*Mosunetuzumab: Hoffmann-la Roche

Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3e), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies.*Tisagenlecleucel: Novartis

Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy that involves genetically modified autologous T cells isolated from each individual patient. The reprogramming of the patient's T cells uses a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR).*Capivasertib: AstraZeneca

Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.*BI-1206: BioInvent

BI-1206 is a high-affinity monoclonal antibody that selectivity binds to Fc?RIIB (CD32B), the only inhibitory member of the Fc?R family. Fc?RIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis in difficult-to treat forms of NHL, such as mantle cell lymphoma. By blocking Fc?RIIB, BI-1206 is expected to recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of these diseases. In January 2023, positive data was presented from the ongoing clinical Phase I/IIa study of BI-1206 in combination with rituximab for the treatment of non-Hodgkin's lymphoma (NHL). Data suggest that BI-1206 restores activity of rituximab in relapsed NHL patients.*HMPL-760: Hutchmed

HMPL-760 is an investigational, highly selective, non-covalent, third-generation inhibitor of BTK, both wild-type and C481S mutant enzymes, with pre-clinical data suggesting high target specificity and higher potency versus first generation BTK inhibitors. BTK C481S mutation plays an important role in resistance to certain BTK inhibitors.

Explore groundbreaking therapies and clinical trials in the Non-Hodgkin Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Non-Hodgkin Lymphoma Drugs

Non-Hodgkin Lymphoma Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration*Oral *Parenteral *intravenous *Subcutaneous *Topical.

Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as*Monoclonal Antibody *Peptides *Polymer *Small molecule *Gene therapy

Unveil the future of Non-Hodgkin Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Non-Hodgkin Lymphoma Market Drivers and Barriers

Scope of the Non-Hodgkin Lymphoma Pipeline Report*Coverage- Global *Non-Hodgkin Lymphoma Companies- Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others. *Non-Hodgkin Lymphoma Pipeline Therapies- Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others. *Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination *Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Non-Hodgkin Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Non-Hodgkin Lymphoma Companies, Key Products and Unmet Needs

Table of Content*Introduction *Executive Summary *Non-Hodgkin Lymphoma: Overview *Pipeline Therapeutics *Therapeutic Assessment *Non-Hodgkin Lymphoma - DelveInsight's Analytical Perspective *Late Stage Products (Phase III) *Tisagenlecleucel: Novartis *Drug profiles in the detailed report..... *Mid Stage Products (Phase II) *Capivasertib: AstraZeneca *Drug profiles in the detailed report..... *Early Stage Products (Phase I/II) *BI-1206: BioInvent *Drug profiles in the detailed report..... *Early Stage Products (Phase I) *HMPL-760: Hutchmed *Drug profiles in the detailed report..... *Preclinical Stage Products *Product Name: Company Name *Drug profiles in the detailed report..... *Inactive Products *Non-Hodgkin Lymphoma Key Companies *Non-Hodgkin Lymphoma Key Products *Non-Hodgkin Lymphoma- Unmet Needs *Non-Hodgkin Lymphoma- Market Drivers and Barriers *Non-Hodgkin Lymphoma- Future Perspectives and Conclusion *Non-Hodgkin Lymphoma Analyst Views *Non-Hodgkin Lymphoma Key Companies *Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact

Company Name: DelveInsight LLP

Contact Person: Yash Bhardwaj

Email: ybhardwaj@delveinsight.com

Phone: +14699457679

Address:304 S. Jones Blvd #2432,

City: Las Vegas

State: United States

Country: India

Website: https://www.delveinsight.com/

Source: www.abnewswire.com

.

(C) 2024 M2 COMMUNICATIONS, source M2 PressWIRE